Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.

Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, Shrank WH.

JAMA. 2008 Dec 3;300(21):2514-26. doi: 10.1001/jama.2008.758. Review.

2.

Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis.

Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, Brookhart MA, Avorn J, Shrank WH.

Drugs. 2010 Mar 26;70(5):605-21. doi: 10.2165/10898530-000000000-00000. Review.

3.

Generic versus brand-name drugs used in cardiovascular diseases.

Manzoli L, Flacco ME, Boccia S, D'Andrea E, Panic N, Marzuillo C, Siliquini R, Ricciardi W, Villari P, Ioannidis JP.

Eur J Epidemiol. 2016 Apr;31(4):351-68. doi: 10.1007/s10654-015-0104-8. Review.

4.
5.

Equivalence of generic and brand-name drugs for cardiovascular disease.

Carter BL.

JAMA. 2009 Apr 22;301(16):1654; author reply 1655-6. doi: 10.1001/jama.2009.520. No abstract available.

PMID:
19383950
6.

Brand name versus generic warfarin: a systematic review of the literature.

Dentali F, Donadini MP, Clark N, Crowther MA, Garcia D, Hylek E, Witt DM, Ageno W; Warfarin Associated Research Projects and Other Endeavors (WARPED) Consortium..

Pharmacotherapy. 2011 Apr;31(4):386-93. doi: 10.1592/phco.31.4.386. Review.

PMID:
21449627
7.

Equivalence of generic and brand-name drugs for cardiovascular disease.

Zema MJ.

JAMA. 2009 Apr 22;301(16):1654-5; author reply 1655-6. doi: 10.1001/jama.2009.521. No abstract available.

PMID:
19383949
8.

Quality of reporting of bioequivalence trials comparing generic to brand name drugs: a methodological systematic review.

van der Meersch A, Dechartres A, Ravaud P.

PLoS One. 2011;6(8):e23611. doi: 10.1371/journal.pone.0023611. Review.

9.

Equivalence of generic and brand-name drugs for cardiovascular disease.

Reiffel JA.

JAMA. 2009 Apr 22;301(16):1655; author reply 1655-6. doi: 10.1001/jama.2009.522. No abstract available.

PMID:
19383951
10.

Similarity between generic and brand-name antihypertensive drugs for primary prevention of cardiovascular disease: evidence from a large population-based study.

Corrao G, Soranna D, Merlino L, Mancia G.

Eur J Clin Invest. 2014 Oct;44(10):933-9. doi: 10.1111/eci.12326.

PMID:
25132063
11.

Are generic and brand-name statins clinically equivalent? Evidence from a real data-base.

Corrao G, Soranna D, Arfè A, Casula M, Tragni E, Merlino L, Mancia G, Catapano AL.

Eur J Intern Med. 2014 Oct;25(8):745-50. doi: 10.1016/j.ejim.2014.08.002.

PMID:
25200803
12.
13.
14.

Meta-analysis for bioequivalence review.

Chow SC, Liu J.

J Biopharm Stat. 1997 Mar;7(1):97-111.

PMID:
9056591
15.

First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.

Xue H, Lu Z, Tang WL, Pang LW, Wang GM, Wong GW, Wright JM.

Cochrane Database Syst Rev. 2015 Jan 11;1:CD008170. doi: 10.1002/14651858.CD008170.pub2. Review.

PMID:
25577154
16.

[Bioequivalence and generics of index drugs with narrow therapeutic margins].

Le Corre P.

Presse Med. 2010 Feb;39(2):169-76. doi: 10.1016/j.lpm.2009.09.017. French.

PMID:
19932591
18.

Are brand-name and generic warfarin interchangeable? A survey of Ontario patients and physicians.

Pereira JA, Holbrook AM, Dolovich L, Goldsmith C, Thabane L, Douketis JD, Crowther M, Bates SM, Ginsberg JS.

Can J Clin Pharmacol. 2005 Fall;12(3):e229-39.

PMID:
16278495
19.

Rational use of generic psychotropic drugs.

Carbon M, Correll CU.

CNS Drugs. 2013 May;27(5):353-65. doi: 10.1007/s40263-013-0045-2. Review.

PMID:
23620145
20.

Is bioavailability altered in generic versus brand anticonvulsants?

Jankovic SM, Ignjatovic Ristic D.

Expert Opin Drug Metab Toxicol. 2015 Mar;11(3):329-32. doi: 10.1517/17425255.2015.989211.

PMID:
25440299
Items per page

Supplemental Content

Support Center